MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

计划入组 100 人 · 首次发布于 2025 年 7 月 20 日

Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor

计划入组 84 人 · 首次发布于 2026 年 7 月 16 日

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

计划入组 123 人 · 首次发布于 2021 年 9 月 28 日

Pexidartinib(Turalio)

C₂₀H₁₅ClF₃N₅

Tag-7 gene modified autologous tumor cell vaccine

Tumor Cell Vaccines(NCI)

Giant Compressed Gases Inc

United States

Stiftung Swiss Tumor Institute

Switzerland

National Center for Tumor Diseases

Germany

Pimicotinib Shows Promise in Phase III Trial for Tenosynovial Giant Cell Tumor

Pimicotinib Meets Primary Endpoint in Phase III Trial for Tenosynovial Giant Cell Tumor

Pimicotinib Shows Significant Improvement in Tenosynovial Giant Cell Tumor Treatment